Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 6
1997 7
1998 7
1999 7
2000 17
2001 19
2002 22
2003 29
2004 25
2005 28
2006 37
2007 36
2008 51
2009 27
2010 26
2011 41
2012 53
2013 56
2014 48
2015 49
2016 58
2017 55
2018 43
2019 55
2020 50
2021 14
Text availability
Article attribute
Article type
Publication date

Search Results

783 results
Results by year
Filters applied: . Clear all
Page 1
Bexarotene Enhances Macrophage Erythrophagocytosis and Hematoma Clearance in Experimental Intracerebral Hemorrhage.
Chang CF, Massey J, Osherov A, Angenendt da Costa LH, Sansing LH. Chang CF, et al. Stroke. 2020 Feb;51(2):612-618. doi: 10.1161/STROKEAHA.119.027037. Epub 2019 Dec 12. Stroke. 2020. PMID: 31826730 Free PMC article.
In vivo, bexarotene treatment enhanced erythrophagocytosis, reduced hematoma volume, and ultimately improved neurological recovery after ICH in 2 distinct models of ICH. Conclusions- Bexarotene administration is beneficial for recovery after ICH by enhancing hemorrh …
In vivo, bexarotene treatment enhanced erythrophagocytosis, reduced hematoma volume, and ultimately improved neurological recovery af …
Bexarotene-induced hypothyroidism: Characteristics and therapeutic strategies.
Makita N, Manaka K, Sato J, Mitani K, Nangaku M, Iiri T. Makita N, et al. Clin Endocrinol (Oxf). 2019 Jul;91(1):195-200. doi: 10.1111/cen.13975. Epub 2019 Apr 11. Clin Endocrinol (Oxf). 2019. PMID: 30903705
This study aimed to characterize the kinetics and dose dependency of bexarotene-induced CH in Japanese patients. DESIGN AND PATIENTS: Sixty-six Japanese patients with CTCL were retrospectively investigated by evaluating thyroid function during the early phase of bexarot
This study aimed to characterize the kinetics and dose dependency of bexarotene-induced CH in Japanese patients. DESIGN AND PATIENTS: …
Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers.
Shen D, Yu X, Wu Y, Chen Y, Li G, Cheng F, Xia L. Shen D, et al. Expert Rev Anticancer Ther. 2018 May;18(5):487-499. doi: 10.1080/14737140.2018.1449648. Epub 2018 Mar 20. Expert Rev Anticancer Ther. 2018. PMID: 29521139 Review.
However, only a subpopulation of bexarotene treated patients benefited from bexarotene administration in most cases. ...Further identification and verification of bexarotene response biomarkers may finally lead to the personalized clinical application of b
However, only a subpopulation of bexarotene treated patients benefited from bexarotene administration in most cases. ...Furthe …
Bexarotene.
Lowe MN, Plosker GL. Lowe MN, et al. Am J Clin Dermatol. 2000 Jul-Aug;1(4):245-50; discussion 251-2. doi: 10.2165/00128071-200001040-00006. Am J Clin Dermatol. 2000. PMID: 11702369 Review.
An overall response rate of 63% was reported after topical bexarotene 0.1 to 1% twice daily in patients with early stage CTCL. ...At clinically relevant oral dosages, bexarotene significantly decreases levels of serum thyrotropin and free thyroxine. ...
An overall response rate of 63% was reported after topical bexarotene 0.1 to 1% twice daily in patients with early stage CTCL. ...At …
Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
Yuan S, Chan JFW, Chik KKH, Chan CCY, Tsang JOL, Liang R, Cao J, Tang K, Chen LL, Wen K, Cai JP, Ye ZW, Lu G, Chu H, Jin DY, Yuen KY. Yuan S, et al. Pharmacol Res. 2020 Sep;159:104960. doi: 10.1016/j.phrs.2020.104960. Epub 2020 May 28. Pharmacol Res. 2020. PMID: 32473310 Free PMC article.
Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abiraterone acetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC(50) 1.13-2.01 muM). Bexarotene demonstra …
Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abiraterone acetate (synthetic androstane steroid), and bex
Activation of retinoid X receptor by bexarotene attenuates neuroinflammation via PPARgamma/SIRT6/FoxO3a pathway after subarachnoid hemorrhage in rats.
Zuo Y, Huang L, Enkhjargal B, Xu W, Umut O, Travis ZD, Zhang G, Tang J, Liu F, Zhang JH. Zuo Y, et al. J Neuroinflammation. 2019 Feb 21;16(1):47. doi: 10.1186/s12974-019-1432-5. J Neuroinflammation. 2019. PMID: 30791908 Free PMC article.
The endovascular perforation induced SAH. Bexarotene was administered intraperitoneally at 1 h after SAH induction. ...CONCLUSIONS: The activation of RXR by bexarotene attenuated neuroinflammation and improved neurological deficits after SAH. ...
The endovascular perforation induced SAH. Bexarotene was administered intraperitoneally at 1 h after SAH induction. ...CONCLUSIONS: T …
Optimized Bexarotene Aerosol Formulation Inhibits Major Subtypes of Lung Cancer in Mice.
Zhang Q, Lee SB, Chen X, Stevenson ME, Pan J, Xiong D, Zhou Y, Miller MS, Lubet RA, Wang Y, Mirza SP, You M. Zhang Q, et al. Nano Lett. 2019 Apr 10;19(4):2231-2242. doi: 10.1021/acs.nanolett.8b04309. Epub 2019 Mar 21. Nano Lett. 2019. PMID: 30873838
Bexarotene has shown inhibition of lung and mammary gland tumorigenesis in preclinical models and in clinical trials. The main side effects of orally administered bexarotene are hypertriglyceridemia and hypercholesterolemia. We previously demonstrated that aerosoliz
Bexarotene has shown inhibition of lung and mammary gland tumorigenesis in preclinical models and in clinical trials. The main side e
Bexarotene ligand pharmaceuticals.
Hurst RE. Hurst RE. Curr Opin Investig Drugs. 2000 Dec;1(4):514-23. Curr Opin Investig Drugs. 2000. PMID: 11249708 Review.
Bexarotene (LGD-1069), from Ligand, was the first retinoid X receptor (RXR)-selective, antitumor retinoid to enter clinical trials. ...Efficacy results exceeded the protocol-defined response target rates; side effects were primarily limited to local skin reactions [349982]
Bexarotene (LGD-1069), from Ligand, was the first retinoid X receptor (RXR)-selective, antitumor retinoid to enter clinical trials. .
Bexarotene-Induced Hypertriglyceridemia: A Case Report.
Maminakis C, Whitman AC, Islam N. Maminakis C, et al. Case Rep Oncol. 2018 Apr 11;11(1):234-238. doi: 10.1159/000488447. eCollection 2018 Jan-Apr. Case Rep Oncol. 2018. PMID: 29805374 Free PMC article.
We present a case of a patient with cutaneous T-cell lymphoma started on bexarotene 300 mg/m(2) due to progressing disease. The patient experienced good clinical response, but unfortunately, she developed rapid and profound hypertriglyceridemia. ...Triglycerides continued …
We present a case of a patient with cutaneous T-cell lymphoma started on bexarotene 300 mg/m(2) due to progressing disease. The patie …
Bexarotene Attenuates Focal Cerebral Ischemia-Reperfusion Injury via the Suppression of JNK/Caspase-3 Signaling Pathway.
Liu H, Liu S, Tian X, Wang Q, Rao J, Wang Y, Xiang F, Zheng H, Xu L, Dong Z. Liu H, et al. Neurochem Res. 2019 Dec;44(12):2809-2820. doi: 10.1007/s11064-019-02902-5. Epub 2019 Nov 3. Neurochem Res. 2019. PMID: 31680194
In conclusion, bexarotene markedly alleviates the neurological deficits, improves the histological outcome, and inhibits cell apoptosis in mice after t-MCAO. This effect is mediated, at least in part, by up-regulation of APOE. Thus, bexarotene may be a candidate dru …
In conclusion, bexarotene markedly alleviates the neurological deficits, improves the histological outcome, and inhibits cell apoptos …
783 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page